首页> 外文期刊>Clinical infectious diseases >Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients
【24h】

Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients

机译:利奈唑胺和达托霉素在耐万古霉素的肠球菌血流感染中的有效性和安全性比较:一项国家队列研究的退伍军人事务患者

获取原文
获取原文并翻译 | 示例
           

摘要

Treatment with daptomycin for vancomycin-resistant enterococcal bloodstream infection resulted in significantly lower treatment failure, 30-day mortality, microbiologic failure, 7-day mortality, and duration of bacteremia in comparison to linezolid.Methods.aEuro integral This was a national retrospective cohort study comparing linezolid and daptomycin for the treatment of VRE-BSI among Veterans Affairs Medical Center patients admitted during 2004-2013. The primary outcome was treatment failure, defined as a composite of (1) 30-day all-cause mortality; (2) microbiologic failure; and (3) 60-day VRE-BSI recurrence. Poisson regression was conducted to determine if antimicrobial treatment was independently associated with clinical outcomes.
机译:与利奈唑胺相比,达托霉素治疗耐万古霉素的肠球菌血液感染可显着降低治疗失败,30天死亡率,微生物学失败,7天死亡率和菌血症持续时间。比较利奈唑胺和达托霉素在2004-2013年间退伍军人事务医学中心的患者中治疗VRE-BSI的情况。主要结果是治疗失败,定义为:(1)30天全因死亡率; (2)微生物学上的失败; (3)60天VRE-BSI复发。进行泊松回归以确定抗生素治疗是否与临床结果独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号